Biologic R&D Cash Outlays Exceed Those For Small Molecules – Tufts Study
Executive Summary
Companies' out-of-pocket expenses to bring a biopharmaceutical to market exceed those for new chemical entities, a Tufts Center for the Study of Drug Development analysis found
You may also be interested in...
Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.
Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
A "split the difference" approach to determining how much exclusivity innovators would receive under a pathway establishing follow-on biologics would give brand products seven years of data exclusivity